drugset / Trial / NCT07290777

VEL-101 to Prevent Rejection After Kidney Transplantation

NCT07290777

Phase 2 Not yet recruiting 120 enrolled Veloxis Pharmaceuticals
RandomizedParallel-groupDouble-blindPrevention

Summary

This study will evaluate the safety and efficacy of VEL-101 compared with tacrolimus in patients undergoing kidney transplantation.

Timeline

Start
2026-07
Primary completion
2028-10
Completion
2028-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tacrolimus Small molecule
Subject pegrizeprument Monoclonal antibody

Indications

No indication recorded.